EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma

Miao Zhang, Tangjia Cai, Shiwei Jin, Xinyun Huang, Yuting Gao, Xiaoyue Chen, Wanyan Ouyang, Yi Tao, Yuanfang Liu, Yan Wang, Hongping Meng, Jian Li und 6 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07219-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Miao Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Multiple Myeloma, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Clinical Research Plan of SHDC, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: [18F]fluorodeoxyglucose (FDG)-PET is a powerful tool to evaluate prognosis in multiple myeloma (MM). The development of systematic and reproducible standard interpretation criteria is crucial for the effective application of FDG-PET in MM. A new set of criteria-Italian Myeloma criteria for PET Use (IMPeTUs)-has standardized PET evaluation in MM. However, the prognostic value of IMPeTUs score remains unknown. METHODS: A total of 58 patients with newly diagnosed multiple myeloma (NDMM) who underwent both [18F]FDG-PET/MRI and PET/CT examinations at diagnosis were enrolled (ChiCTR1900022597). All patients completed a 42-month follow-up. The prognostic value of the PET/MRI (or PET/CT) IMPeTUs score in predicting progression-free (PFS) and overall (OS) survival was compared with that of individual laboratory parameters and the maximum standardized uptake value (SUVmax). Kaplan-Meier method was used for survival analysis. Univariate and multivariate analyses of prognostic factors were conducted using Cox regression. RESULTS: ROC curves demonstrated that the area under the curve for the PET/MRI IMPeTUs score was 0.760, exceeding that of the PET/CT IMPeTUs score (0.711), PET/CT BM SUVmax (0.649), PET/MRI BM SUVmax (0.575), bone marrow plasma cells (0.500), and β2-microglobulin (0.501). Univariate analysis and Kaplan-Meier analysis showed that a PET/MRI IMPeTUs score ≥ 13 and PET/CT IMPeTUs score ≥ 10 were significantly associated with worse PFS. Cox multivariate analysis showed that a PET/MRI IMPeTUs score ≥ 13 was an independent risk factor for PFS. CONCLUSION: IMPeTUs standardized [18F]FDG-PET/MRI and PET/CT readings in MM. The IMPeTUs score is crucial for predicting MM prognosis, performing better than SUVmax and clinical indicators. CLINICAL TRIAL REGISTRATION: ChiCTR1900022597, Registered on 18 April 2019.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Magnetic Resonance ImagingMultiple MyelomaPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedPrognosisRadiopharmaceuticals

Stichwörter der Autor:innen

Italian myeloma criteria for pet use (IMPeTUs )Multiple myeloma (MM)PET/CT[18F]fluorodeoxyglucose (FDG) PET/MRI

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 2…
  • Clinical Research Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
  • Department of Nuclear Medicine, University of Bern, Bern, Switzerland.
  • Department of Interventional Radiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. dxy10456@rjh.com.cn.
  • Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. lb10363@rjh.com.cn.

ORCID-Profile: Biao Li

Förderung

  • National Natural Science Foundation of China
  • Clinical Research Plan of SHDC
  • Shanghai Municipal Health Commission
  • Guangci Clinical Technology and Innovation Program(GCTIP)of Ruijin Hospital

Zitieren

APA

Zhang, M., Cai, T., Jin, S., Huang, X., Gao, Y., Chen, X., Ouyang, W., Tao, Y., Liu, Y., Wang, Y., Meng, H., Li, J., Lin, X., Shi, K., Wang, J., Ding, X., Mi, J. Q., & Li, B. (2025). Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07219-w

Vancouver

Zhang M, Cai T, Jin S, Huang X, Gao Y, Chen X, et al. Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07219-w

BibTeX
@article{Zhang2025,
  author = {Zhang, Miao and Cai, Tangjia and Jin, Shiwei and Huang, Xinyun and Gao, Yuting and Chen, Xiaoyue and Ouyang, Wanyan and Tao, Yi and Liu, Yuanfang and Wang, Yan and Meng, Hongping and Li, Jian and Lin, Xiaozhu and Shi, Kuangyu and Wang, Jin and Ding, Xiaoyi and Mi, Jian-Qing and Li, Biao},
  title = {Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07219-w}
}
Kostenlos starten →